Literature DB >> 25525271

Epidermal growth factor activates the Rho GTPase-activating protein (GAP) Deleted in Liver Cancer 1 via focal adhesion kinase and protein phosphatase 2A.

Archna Ravi1, Shelly Kaushik1, Aarthi Ravichandran2, Catherine Qiurong Pan2, Boon Chuan Low3.   

Abstract

Deleted in Liver Cancer 1 (DLC1) is a RHO GTPase-activating protein (GAP) that negatively regulates RHO. Through its GAP activity, it modulates the actin cytoskeleton network and focal adhesion dynamics, ultimately leading to suppression of cell invasion and metastasis. Despite its presence in various structural and signaling components, little is known about how the activity of DLC1 is regulated at focal adhesions. Here we show that EGF stimulation activates the GAP activity of DLC1 through a concerted mechanism involving DLC1 phosphorylation by MEK/ERK and its subsequent dephosphorylation by protein phosphatase 2A (PP2A) and inhibition of focal adhesion kinase by MEK/ERK to allow the binding between DLC1 and PP2A. Phosphoproteomics and mutation studies revealed that threonine 301 and serine 308 on DLC1, known previously to be mutated in certain cancers, are required for DLC1-PP2A interaction and the subsequent activation of DLC1 upon their dephosphorylation. The intricate interplay of this "MEK/ERK-focal adhesion kinase-DLC1-PP2A" quartet provides a novel checkpoint in the spatiotemporal control of cell spreading and cell motility.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Deleted In Liver Cancer 1 (DLC1); Focal Adhesion Kinase (FAK); GTPase-activating Protein (GAP); MEK/ERK; PTK2 Protein-tyrosine Kinase 2 (PTK2); Phosphorylation; Protein Phosphatase 2 (PP2A)

Mesh:

Substances:

Year:  2014        PMID: 25525271      PMCID: PMC4326825          DOI: 10.1074/jbc.M114.616839

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

Review 1.  Rho and Rac take center stage.

Authors:  Keith Burridge; Krister Wennerberg
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

2.  Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK).

Authors:  Guorong Li; Xiaoli Du; William C Vass; Alex G Papageorge; Douglas R Lowy; Xiaolan Qian
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-03       Impact factor: 11.205

3.  Akt phosphorylation of deleted in liver cancer 1 abrogates its suppression of liver cancer tumorigenesis and metastasis.

Authors:  Frankie Chi Fat Ko; Lo-Kong Chan; Edmund Kwok-Kwan Tung; Scott W Lowe; Irene Oi-Lin Ng; Judy Wai Ping Yam
Journal:  Gastroenterology       Date:  2010-06-20       Impact factor: 22.682

4.  FAK phosphorylation by ERK primes ras-induced tyrosine dephosphorylation of FAK mediated by PIN1 and PTP-PEST.

Authors:  Yanhua Zheng; Yan Xia; David Hawke; Maxime Halle; Michel L Tremblay; Xiang Gao; Xiao Zhen Zhou; Kenneth Aldape; Melanie H Cobb; Keping Xie; Jie He; Zhimin Lu
Journal:  Mol Cell       Date:  2009-07-10       Impact factor: 17.970

5.  Overexpression of DLC-1 induces cell apoptosis and proliferation inhibition in the renal cell carcinoma.

Authors:  Tao Zhang; Jingcun Zheng; Ning Jiang; Guozeng Wang; Quan Shi; Chunfang Liu; Yuan Lu
Journal:  Cancer Lett       Date:  2009-04-19       Impact factor: 8.679

Review 6.  Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility.

Authors:  T Y Kim; D Vigil; C J Der; R L Juliano
Journal:  Cancer Metastasis Rev       Date:  2009-06       Impact factor: 9.264

7.  Antitumor antibiotic fostriecin covalently binds to cysteine-269 residue of protein phosphatase 2A catalytic subunit in mammalian cells.

Authors:  Toshifumi Takeuchi; Noriyuki Takahashi; Kazutomo Ishi; Tomoe Kusayanagi; Kouji Kuramochi; Fumio Sugawara
Journal:  Bioorg Med Chem       Date:  2009-10-03       Impact factor: 3.641

8.  The SAM domain of the RhoGAP DLC1 binds EF1A1 to regulate cell migration.

Authors:  Dandan Zhong; Jingfeng Zhang; Shuai Yang; Unice J K Soh; Jan Paul Buschdorf; Yi Ting Zhou; Daiwen Yang; Boon Chuan Low
Journal:  J Cell Sci       Date:  2009-02-01       Impact factor: 5.285

Review 9.  Focal adhesion kinase: switching between GAPs and GEFs in the regulation of cell motility.

Authors:  Alok Tomar; David D Schlaepfer
Journal:  Curr Opin Cell Biol       Date:  2009-06-12       Impact factor: 8.382

10.  Deleted in liver cancer 1 (DLC1) utilizes a novel binding site for Tensin2 PTB domain interaction and is required for tumor-suppressive function.

Authors:  Lo-Kong Chan; Frankie Chi Fat Ko; Irene Oi-Lin Ng; Judy Wai Ping Yam
Journal:  PLoS One       Date:  2009-05-15       Impact factor: 3.240

View more
  14 in total

1.  Tensin1 positively regulates RhoA activity through its interaction with DLC1.

Authors:  Yi-Ping Shih; Peng Sun; Aifeng Wang; Su Hao Lo
Journal:  Biochim Biophys Acta       Date:  2015-09-28

2.  Down-regulation of DLC1 in endothelial cells compromises the angiogenesis process.

Authors:  Yi-Ping Shih; Sarah Y Yuan; Su Hao Lo
Journal:  Cancer Lett       Date:  2017-04-10       Impact factor: 8.679

Review 3.  Regulating Rho GTPases and their regulators.

Authors:  Richard G Hodge; Anne J Ridley
Journal:  Nat Rev Mol Cell Biol       Date:  2016-06-15       Impact factor: 94.444

4.  Targeting cell surface GRP78 enhances pancreatic cancer radiosensitivity through YAP/TAZ protein signaling.

Authors:  Udhayakumar Gopal; Yvonne Mowery; Kenneth Young; Salvatore Vincent Pizzo
Journal:  J Biol Chem       Date:  2019-07-29       Impact factor: 5.157

5.  fMLP-dependent activation of Akt and ERK1/2 through ROS/Rho A pathways is mediated through restricted activation of the FPRL1 (FPR2) receptor.

Authors:  Wissam H Faour; Hussein Fayyad-Kazan; Nabil El Zein
Journal:  Inflamm Res       Date:  2018-06-19       Impact factor: 4.575

6.  Curcumin inhibits growth of human breast cancer cells through demethylation of DLC1 promoter.

Authors:  Yufei Liu; Jun Zhou; Yuchang Hu; Junjie Wang; Chengfu Yuan
Journal:  Mol Cell Biochem       Date:  2016-11-10       Impact factor: 3.396

7.  ARHGAP24 inhibits cell cycle progression, induces apoptosis and suppresses invasion in renal cell carcinoma.

Authors:  Gaosi Xu; Xiongbing Lu; Tianlun Huang; Jie Fan
Journal:  Oncotarget       Date:  2016-08-09

8.  Chloride-hydrogen antiporters ClC-3 and ClC-5 drive osteoblast mineralization and regulate fine-structure bone patterning in vitro.

Authors:  Quitterie C Larrouture; Deborah J Nelson; Lisa J Robinson; Li Liu; Irina Tourkova; Paul H Schlesinger; Harry C Blair
Journal:  Physiol Rep       Date:  2015-11-24

9.  Disruption and inactivation of the PP2A complex promotes the proliferation and angiogenesis of hemangioma endothelial cells through activating AKT and ERK.

Authors:  Furong Xie; Xin Bao; Jingshuang Yu; Wantao Chen; Lizhen Wang; Zhiyuan Zhang; Qin Xu
Journal:  Oncotarget       Date:  2015-09-22

10.  DLC-1 is an independent prognostic marker and potential therapeutic target in hepatocellular cancer.

Authors:  L J Song; Q Liu; X R Meng; Sh L Li; L X Wang; Q X Fan; X Y Xuan
Journal:  Diagn Pathol       Date:  2016-02-04       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.